Our Company

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation.

Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics has 65+ employees and is listed on Euronext Paris.

Corporate presentation

Breaking through the therapeutic ceiling with first-in-class immunotherapies

Download our Corporate Presentation

Presentation post-ASCO 2022

ASCO results & Tedopi® update, June 7th 2022

Download our Presentation post-ASCO 2022

Management team

The Company relies upon its international and complementary team of experts involved in the research and optimisation of drug candidates, pharmaceutical development and drug registration to develop the next wave of novel immunotherapies.

Nicolas Poirier, PhD

Chief Executive Officer

Dominique Costantini, MD

Director of development

Anne-Laure Autret-Cornet

Chief Financial Officer

Silvia Comis

Head of Clinical Development

Jean-Pascal Conduzorgues, PharmD

Chief Manufacturing Officer and Qualified Person (QP)

Board of Directors

Members of the Board of Directors combine international expertise in both drug development, marketing, industry and finance, with experience in listed biotech companies.

Scientific Advisory Board

The Scientific Advisory Board (SAB) combines the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy.

Immunologist and Doctor in veterinary sciences, Director of Research at the Institut National de la Santé et Recherche Médicale (INSERM, National Institute for Health and Medical Research) in Nantes

Bernard Malissen, PhD

Group Leader at Centre d’Immunologie de Marseille-Luminy and Founding-Director of Center for Immunophenomics, Marseille, France

Myriam Merad, MD, PhD

Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC)

Charles N. Serhan, PhD, DSc

Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School, Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine

Our Company

Corporate presentation

Presentation post-ASCO 2022

Management team

Nicolas Poirier, PhD

Chief Executive Officer

Dominique Costantini, MD

Director of development

Anne-Laure Autret-Cornet

Chief Financial Officer

Silvia Comis

Head of Clinical Development

Jean-Pascal Conduzorgues, PharmD

Chief Manufacturing Officer and Qualified Person (QP)

Board of Directors

Dominique Costantini, MD

Chairwoman and Director of development

Maryvonne Hiance

Vice Chairwoman

Nicolas Poirier, PhD

Director representing the employee shareholders and Chief Executive Officer

Elsy Boglioli

Director

Jean-Patrick Demonsang

Director

Brigitte Dreno, MD

Director

Didier Hoch, MD

Director

Alexandre Lebeaut, MD

Director

Gérard Tobelem, MD

Director

Scientific Advisory Board

Wolf-Hervé Fridman, MD

Chairman of the SAB, Professor Emeritus of Immunology at the 'Université de Paris' in Paris, France

Sophie Brouard, PhD

Immunologist and Doctor in veterinary sciences, Director of Research at the Institut National de la Santé et Recherche Médicale (INSERM, National Institute for Health and Medical Research) in Nantes

Bernard Malissen, PhD

Group Leader at Centre d’Immunologie de Marseille-Luminy and Founding-Director of Center for Immunophenomics, Marseille, France

Myriam Merad, MD, PhD

Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC)

Charles N. Serhan, PhD, DSc

Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School, Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine

Jennifer Wargo, MD, M.M.Sc

Professor of Genomic Medicine & Surgical Oncology, UT MD Anderson Cancer Center

To receive OSE Immunotherapeutics’ latest news